ABBV 321

Drug Profile

ABBV 321

Alternative Names: ABBV-321

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AbbVie
  • Class Antineoplastics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 Oct 2017 Phase-I clinical trials in Solid tumours (Late-stage disease) in Australia, USA (IV) (NCT03234712)
  • 08 Aug 2017 Preclinical trials in Solid tumours in USA before August 2017 (IV)
  • 31 Jul 2017 AbbVie plans a phase I trial for Solid tumours (Late-stage disease) (NCT03234712)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top